Abstract
Ravulizumab is an anti-C5 antibody approved for treating paroxysmal nocturnal hemoglobinuria (PNH). In August 2019, a 77-year-old Japanese man with PN......
小提示:本篇文献需要登录阅读全文,点击跳转登录